Showing 1931-1940 of 5963 results for "".
- Topix Pharmaceuticals Introduces Its New Backbar Linehttps://practicaldermatology.com/news/topix-pharmaceuticals-introduces-its-new-backbar-line/2457572/Topix Pharmaceuticals, Inc. is rolling out its Backbar Line, a collection of 10 professional products that allows physicians to use their own branding. Only available for sale direct to office, the line is designed to support procedures and non-i
- Ekwa Marketing Launches Affiliate Program, Offers Residual Income Opportunity for Medical Associationshttps://practicaldermatology.com/news/ewa-marketing-launches-affiliate-program-offers-residual-income-opportunity-for-medical-associations/2457622/Ekwa Marketing has launched its unique Ekwa Affiliate Program. Medical associations can simply place an online link to Ekwa’s innovative digital marketing products for doctors on their website and social media networks, and start receiving a passive i
- Adam Friedman, MD Wins Innovations in Residency Training Awardhttps://practicaldermatology.com/news/adam-friedman-md-wins-innovations-in-residency-training-award/2457920/The Journal of Drugs in Dermatology (JDD) awarded Adam Friedman, MD, FAAD with the Innovations in Residency Training Award at the recent Orlando Dermatology Aesthetic & Clinical Conference (ODAC) held in Miami. The award recognizes individuals who have fostered innovation and i
- FDA Accepts Ortho Dermatologic's NDA for Novel Plaque Psoriasis Treatment, IDP-118https://practicaldermatology.com/news/fda-accepts-ortho-dermatologics-nda-for-novel-plaque-psoriasis-treatment-idp-118/2457988/The US Food and Drug Administration has accepted Ortho Dermatologic's New Drug Application (NDA) for IDP-118 (halobetasol propionate and tazarotene) lotion, an investigational topical treatment for plaque psoriasis. The PDUFA action date i
- Can Vaseline Protect High-Risk Infants from Eczema? Study Says Yeshttps://practicaldermatology.com/news/can-vaseline-protect-high-risk-infants-from-eczema-study-says-yes/2458353/Applying low-cost moisturizers including petroleum jelly to a baby's skin for the first six months of his or her life is a cost-effective way to prevent eczema, finds a new study published in JAMA Pediatrics. Seven common moisturizers are cost effective in preventing eczema i
- FDA Clears Syneron Candela's Profound SubQ to Improve Cellulitehttps://practicaldermatology.com/news/fda-clears-syneron-candelas-profound-subq-to-improve-cellulite/2458381/Syneron Candela received FDA 510(k) clearance for Profound when using the SubQ handpiece and cartridge to improve the appearance of cellulite in patients with Fitzpatrick skin types I-III, as supported by long term data (6 months). A recent multi-center clinical study of Profound sh
- Biosimilar News: Sandoz Acquires Biosimilar Infliximab In EEA, FDA Panel Urges Approval of Biosimilar Infliximab in UShttps://practicaldermatology.com/news/biosimilar-new-sandoz-acquires-biosimilar-infliximab-in-eea-fda-panel-urges-approval-of-biosimilar-infliximab-in-us/2458705/Two days after a US Food and Drug Administration (FDA) advisory panel voted to recommend approval of the biosimilar form of Remicade (Infliximab), Novartis’ Sandoz unit has acquired rights to develop and commercialize a biosimilar to Remicade® (i
- Vyome Biosciences: FDA Has Accepted IND for Investigational Acne Therapyhttps://practicaldermatology.com/news/vyome-biosciences-fda-has-accepted-ind-for-investigational-acne-therapy/2458728/The FDA has accepted from Vyome Biosciences an Investigational New Drug (IND) Application for the initiation of clinical studies for its lead program VB 1953, a topical therapeutic candidate for the treatment of moderate-to-severe acne. Vyome plans to start the Phase I clinical trials very soon.<
- Indoor Tanning Linked to Teen Substance Abusehttps://practicaldermatology.com/news/indoor-tanning-linked-to-teen-substance-abuse/2458742/New research links teen indoor tanning with substance abuse. In a study of Colorado high school students, teens who took steroids were among the most likely to use tanning beds, especially adolescent boys. Alcohol consumption in the past 30 days, marijuana use and lifetime use of select i
- Vyome Biosciences Announces FDA Acceptance of Investigational New Drug Application for VB-1953 to Treat Acnehttps://practicaldermatology.com/news/vyome-biosciences-announces-fda-acceptance-of-investigational-new-drug-application-for-vb-1953-to-treat-acne/2458766/The FDA accepted Vyome Biosciences’ Investigational New Drug (IND) Application for the initiation of clinical studies for VB 1953, a topical therapeutic candidate for the treatment of moderate-to-severe acne. Vyome plans to start the Phase I clinical trials very soon. “Today m